
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
The U-2932 cell line was established in 1996 from the ascites of a 29-year-old female patient with diffuse large B-cell lymphoma (DLBCL), following a history of advanced-stage Hodgkin lymphoma treated with multiple chemotherapy and radiotherapy regimens. The cells belong to the activated B-cell (ABC-like) subtype of DLBCL and have been reported to overexpress BCL2, BCL6, and p53. U-2932 contains two distinct subpopulations with different surface expression patterns of CD19, CD20, and CD38, reflecting intraline heterogeneity. This human lymphoma cell line is used as a model for studying B-cell malignancies, tumor heterogeneity, molecular alterations, and therapeutic responses in diffuse large B-cell lymphoma.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?